Literature DB >> 1554497

Immunodeficiency with hyper-IgM (HIM).

L D Notarangelo1, M Duse, A G Ugazio.   

Abstract

Immunodeficiency with hyper-IgM (HIM) is a rare disorder characterized by recurrent infections associated with low IgG and IgA, and normal to increased IgM serum levels. Both primary and secondary forms of HIM syndrome have been reported. Among primary HIM syndrome, evidence for genetic heterogeneity is provided by the occurrence of the disease as X-linked, autosomal recessive, or autosomal dominant trait. The most common clinical manifestations include upper and lower respiratory tract infections, otitis, diarrhoea, oral ulcers, lymphoid hyperplasia, and autoimmunity. Recurrent neutropaenia is a frequent finding. Immunological abnormalities consist of lack of IgG and IgA secretion, and failure to respond to vaccination. Lymph nodes show absence of germinal centres. Few patients with a concurrent T-cell defect, and clinical expression of combined immune deficiency, have been reported. The gene responsible for the X-linked HIM syndrome (HIGM1) has been tentatively assigned to Xq24-27. However, carrier detection and prenatal diagnosis are not yet possible. Pathogenetic hypotheses include failure of B-cell differentiation, and defective regulation of immunoglobulin isotype switching due to abnormal T-cell-mediated signals. Treatment is mainly based upon regular administration of intravenous immunoglobulins. Steroids may be useful in the treatment of neutropaenia and of severe autoimmune manifestations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1554497

Source DB:  PubMed          Journal:  Immunodefic Rev        ISSN: 0893-5300


  92 in total

Review 1.  Pitfalls of "hyper"-IgM syndrome: a new CD40 ligand mutation in the presence of low IgM levels. A case report and a critical review of the literature.

Authors:  A Heinold; B Hanebeck; V Daniel; J Heyder; T H Tran; B Döhler; J Greil; F-M Müller
Journal:  Infection       Date:  2010-10-28       Impact factor: 3.553

Review 2.  Age effects on B cells and humoral immunity in humans.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Ana Marie Landin; Bonnie B Blomberg
Journal:  Ageing Res Rev       Date:  2010-08-20       Impact factor: 10.895

Review 3.  CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes.

Authors:  A Bhushan; L R Covey
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 4.  Periodontal and other oral manifestations of immunodeficiency diseases.

Authors:  M E Peacock; R M Arce; C W Cutler
Journal:  Oral Dis       Date:  2016-10-10       Impact factor: 3.511

Review 5.  The CD40 ligand. At the center of the immune universe?

Authors:  I S Grewal; R A Flavell
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

Review 6.  Hyper IgM syndrome: two mutations distinguish HIM.

Authors:  T M Foy; S R Masters; R J Noelle
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

7.  T cell clones from an X-linked hyper-immunoglobulin (IgM) patient induce IgE synthesis in vitro despite expression of nonfunctional CD40 ligand.

Authors:  P Life; J F Gauchat; V Schnuriger; S Estoppey; G Mazzei; A Durandy; A Fischer; J Y Bonnefoy
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

8.  Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome.

Authors:  L E Leiva; J Junprasert; D Hollenbaugh; R U Sorensen
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

9.  An imbalance of naive and memory/effector subsets and altered expression of CD38 on T lymphocytes in two girls with hyper-IgM syndrome.

Authors:  B T Costa-Carvalho; M A Viana; M K C Brunialti; E G Kallas; R Salomao
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

Review 10.  Molecular and genetic basis of X-linked immunodeficiency disorders.

Authors:  J M Puck
Journal:  J Clin Immunol       Date:  1994-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.